Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
Globe Newswire•27/10/2026•16:05 ET
0
Key Highlights
- ➤AN4035 abstract selected for oral presentation at the 38th ENA Symposium
- ➤AN4035 presentation will include translational and EGFR combination data
- ➤AN4035 is a CEACAM5-targeting ADC with a proprietary pan-RAS(ON) inhibitor payload
- ➤Global Phase I trial is evaluating AN4035 in CEACAM5-enriched RAS-addicted solid tumors
- ➤AN4035 showed deep tumor regression in CEACAM5-positive preclinical models
Expert Statements
Archie Tse, President and Head of Research & Development at Adlai Nortye
“We are delighted that an AN4035 abstract has been selected for an oral presentation at ENA for the second time.”
Archie Tse, President and Head of Research & Development at Adlai Nortye
“At this year’s meeting, we will share translational and combination data supporting the ongoing Phase I study of AN4035, including its evaluation with EGFR blockade.”
Archie Tse, President and Head of Research & Development at Adlai Nortye
“AN4035 is a first-in-class ADC targeting CEACAM5 armed with a proprietary pan-RAS(ON) inhibitor payload.”
Archie Tse, President and Head of Research & Development at Adlai Nortye
“By selectively delivering the payload to CEACAM5-expressing tumors, AN4035 is designed to broaden the therapeutic window and support combination with cetuximab.”
Archie Tse, President and Head of Research & Development at Adlai Nortye
“We look forward to discussing this important work with the oncology community and advancing the clinical development of AN4035.”
AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona
Oral presentation will include translational and EGFR combination data for first-in-class AN4035
Get started
Create a free account to read the full story.